MedTrace Logo

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

NCT01730417 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-11-21

No results posted yet for this study

Summary

The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.

Conditions

Interventions

DRUG

no carrier added metaiodobenzylguanidine

Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Molecular Insights Pharmaceuticals

    collaborator UNKNOWN

  • Bennett Chin

    lead OTHER

Principal Investigators

  • Bennett B Chin, MD · Duke University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01730417 on ClinicalTrials.gov